Allena Pharmaceuticals, Inc. Additional Paid In Capital

Additional Paid In Capital of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Additional Paid In Capital growth rates and interactive chart.


Highlights and Quick Summary

  • Additional Paid In Capital for the quarter ending March 31, 2022 was $270 Million (a 1.72% increase compared to previous quarter)
  • Year-over-year quarterly Additional Paid In Capital increased by 14.51%
  • Annual Additional Paid In Capital for 2021 was $265 Million (a 20.39% increase from previous year)
  • Annual Additional Paid In Capital for 2020 was $220 Million (a 20.97% increase from previous year)
  • Annual Additional Paid In Capital for 2019 was $182 Million (a 9.03% increase from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Additional Paid In Capital of Allena Pharmaceuticals, Inc.

Most recent Additional Paid In Capitalof ALNA including historical data for past 10 years.

Interactive Chart of Additional Paid In Capital of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Additional Paid In Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $269.79
2021 $265.24 $262.04 $235.61 $232.87 $265.24
2020 $220.31 $205.67 $197.85 $183.16 $220.31
2019 $182.12 $178.75 $177.95 $167.68 $182.12
2018 $167.04 $166.42 $165.82 $165.23 $167.04
2017 $164.81 $1.28 $0.0 $0.0 $164.81
2016 $0.0 $1.03
2015 $0.83 $0.83

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.